Maria V. Podryadnova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria V. Podryadnova has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Margarita M. Urumova
V.A. Nasonova Research Institute of Rheumatology
3 shared publications - Svetlana I. Glukhova
Nasonova Research Institute of Rheumatology
3 shared publications - Ekaterina M. Agafonova
V.A. Nasonova Research Institute of Rheumatology
2 shared publications - Ekaterina V. Ilinykh
V.A. Nasonova Research Institute of Rheumatology
2 shared publications - Elena E. Gubar
V.A. Nasonova Research Institute of Rheumatology
2 shared publications - Elena Yu. Loginova
V.A. Nasonova Research Institute of Rheumatology
2 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 202-208
Quality of life in men with rheumatoid arthritis and testosterone deficiency
Introduction . Low testosterone levels are common in men with rheumatoid arthritis (RA). Patients with RA and hypogonadism have higher levels, reflecting systemic inflammation. Both RA and hypogonadism can negatively impact quality of life. Aim. To assess the impact of low testosterone levels on quality of life in men with RA. Materials and methods . A cross-sectional study of 73 men diagnosed with RA was conducted. All patients had their total blood testosterone levels measured and were administered the HAQ, EQ-5D, and HADS questionnaires. A cross-sectional comparison of quantitative and qualitative parameters was performed between normal and low (≤12.0 nmol/L) total blood testosterone levels. Results . Patients with hypogonadism and RA were characterized by lower quality of life indicators, which was reflected in the results of the HAQ questionnaires (1.59 ± 0.88 vs. 1.09 ± 0.87; p = 0.036), EQ-5D (0.52 [-0.01; 0.64] vs. 0.62 [0.52; 0.69]; p = 0.048), as well as the patient’s assessment of the general condition using VAS (70.0 [60.0; 80.0] vs. 60.0 [55.0; 70.0]; p = 0.039). The results of the HADS questionnaire were comparable in the studied subgroups. In the correlation analysis, the HAQ score correlated with RA activity according to DAS28CRP (r = 0.58; p < 0.001), ESR (ρ = 0.51; p < 0.001) and CRP (ρ = 0.55; p < 0.001), as well as the class of functional impairment (ρ = 0.26; p = 0.025), total testosterone (ρ = -0.3; p = 0.009) and hemoglobin (ρ = -0.48; p < 0.001). High RA activity (DAS28CRP ≥ 5.1), but not the presence of hypogonadism, as well as factors related to age and body weight, significantly increased the likelihood of having more negative results according to the HAQ questionnaire: OR 17.5; 95% CI 4.5–68.1 (p < 0.001) for HAQ ≥ 1.0 and OR 18.12; 95% CI 1.03–319.23 (p = 0.048) for HAQ ≥ 2.0. Conclusion. Patients with RA and hypogonadism have a lower quality of life, which is due to the influence of inflammatory activity.
- 14 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 202-208
Open AccessQuality of life in men with rheumatoid arthritis and testosterone deficiency
Introduction . Low testosterone levels are common in men with rheumatoid arthritis (RA). Patients with RA and hypogonadism have higher levels, reflecting systemic inflammation. Both RA and hypogonadism can negatively impact quality of life. Aim. To assess the impact of low testosterone levels on quality of life in men with RA. Materials and methods . A cross-sectional study of 73 men diagnosed with RA was conducted. All patients had their total blood testosterone levels measured and were administered the HAQ, EQ-5D, and HADS questionnaires. A cross-sectional comparison of quantitative and qualitative parameters was performed between normal and low (≤12.0 nmol/L) total blood testosterone levels. Results . Patients with hypogonadism and RA were characterized by lower quality of life indicators, which was reflected in the results of the HAQ questionnaires (1.59 ± 0.88 vs. 1.09 ± 0.87; p = 0.036), EQ-5D (0.52 [-0.01; 0.64] vs. 0.62 [0.52; 0.69]; p = 0.048), as well as the patient’s assessment of the general condition using VAS (70.0 [60.0; 80.0] vs. 60.0 [55.0; 70.0]; p = 0.039). The results of the HADS questionnaire were comparable in the studied subgroups. In the correlation analysis, the HAQ score correlated with RA activity according to DAS28CRP (r = 0.58; p < 0.001), ESR (ρ = 0.51; p < 0.001) and CRP (ρ = 0.55; p < 0.001), as well as the class of functional impairment (ρ = 0.26; p = 0.025), total testosterone (ρ = -0.3; p = 0.009) and hemoglobin (ρ = -0.48; p < 0.001). High RA activity (DAS28CRP ≥ 5.1), but not the presence of hypogonadism, as well as factors related to age and body weight, significantly increased the likelihood of having more negative results according to the HAQ questionnaire: OR 17.5; 95% CI 4.5–68.1 (p < 0.001) for HAQ ≥ 1.0 and OR 18.12; 95% CI 1.03–319.23 (p = 0.048) for HAQ ≥ 2.0. Conclusion. Patients with RA and hypogonadism have a lower quality of life, which is due to the influence of inflammatory activity.
- Open Access
- 13 June 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (5) , 282-289
Combined comorbid pathology in axial spondyloarthritis
Aim. To analyze the frequency of combined comorbid pathology and its effect on clinical and instrumental characteristics in axial spondyloarthritis (SpA), including axial psoriatic arthritis. Materials and methods. 222 patients were included in the study: 108 with axial SpA, 114 with axial psoriatic arthritis. The average age was 40.9±12.4 years, and the duration of inflammatory back pain was 68±53.3 months. A standard rheumatological examination, X-ray of the cervical and lumbar spine, and pelvis were performed. The activity of spondylitis was determined by BASDAI and ASDAS-CRP. The patients were divided into 3 groups: 1st – without comorbid diseases (CD) – 66 (29.7%) patients, 2nd – with 1–2 CD – 78 (35.1%), 3rd – with ≥3 CD – 78 (35.1%). Results. The patients in 3rd group were older than in the other groups (in 1st group – 39±12.1 years, in 2nd – 39±11.2, in 3rd – 44.5±13.1; p1-3=0.039, p2-3=0.028), they had a higher level of Pain (in the 1st – 54.3±19.7 mm VAS, in the 2nd – 51.1±22.7, in the 3rd – 63.3±19.4; p=0.01 for all comparisons), the ASDAS-CRP value was higher than in the 1st group (in the 1st – 2.2±1.1, in the 2nd – 2.6±1.1, 3rd – 2.7±0.9; p1-3=0.01), syndesmophytes were more common in the cervical and/or lumbar spine, ankylosis of the faceted joints in the cervical spine (p 0.05). The results of the cluster analysis allowed us to group the features into 4 main clusters. The first cluster, in which the ASDAS-CRP and BASDAI indices were grouped, is combined, on the one hand, with a cluster with the presence of psoriasis, comorbidity (≥3), and structural changes in the spine, on the other hand, with other CD and extra-skeletal manifestations of SpA. Conclusion. The presence of a combination of CD was associated with higher activity of spondylitis, more common structural injuries of the spine. The choice of therapy, taking into account СD and extra-skeletal manifestations of SpA, should improve patient treatment outcomes.
- 13 June 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (5) , 282-289
Open AccessCombined comorbid pathology in axial spondyloarthritis
Aim. To analyze the frequency of combined comorbid pathology and its effect on clinical and instrumental characteristics in axial spondyloarthritis (SpA), including axial psoriatic arthritis. Materials and methods. 222 patients were included in the study: 108 with axial SpA, 114 with axial psoriatic arthritis. The average age was 40.9±12.4 years, and the duration of inflammatory back pain was 68±53.3 months. A standard rheumatological examination, X-ray of the cervical and lumbar spine, and pelvis were performed. The activity of spondylitis was determined by BASDAI and ASDAS-CRP. The patients were divided into 3 groups: 1st – without comorbid diseases (CD) – 66 (29.7%) patients, 2nd – with 1–2 CD – 78 (35.1%), 3rd – with ≥3 CD – 78 (35.1%). Results. The patients in 3rd group were older than in the other groups (in 1st group – 39±12.1 years, in 2nd – 39±11.2, in 3rd – 44.5±13.1; p1-3=0.039, p2-3=0.028), they had a higher level of Pain (in the 1st – 54.3±19.7 mm VAS, in the 2nd – 51.1±22.7, in the 3rd – 63.3±19.4; p=0.01 for all comparisons), the ASDAS-CRP value was higher than in the 1st group (in the 1st – 2.2±1.1, in the 2nd – 2.6±1.1, 3rd – 2.7±0.9; p1-3=0.01), syndesmophytes were more common in the cervical and/or lumbar spine, ankylosis of the faceted joints in the cervical spine (p 0.05). The results of the cluster analysis allowed us to group the features into 4 main clusters. The first cluster, in which the ASDAS-CRP and BASDAI indices were grouped, is combined, on the one hand, with a cluster with the presence of psoriasis, comorbidity (≥3), and structural changes in the spine, on the other hand, with other CD and extra-skeletal manifestations of SpA. Conclusion. The presence of a combination of CD was associated with higher activity of spondylitis, more common structural injuries of the spine. The choice of therapy, taking into account СD and extra-skeletal manifestations of SpA, should improve patient treatment outcomes.
- Open Access
- 2 March 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (1) , 53-59
Features of coxitis in spondyloarthritis
According to an epidemiological study, hip joint involvement was detected in 12–56% of patients with axial spondyloarthritis (axSpA) in Russia. Data on the incidence of coxitis in patients with axial psoriatic arthritis (axPsA) are lacking. The aim of the study was to compare radiographic changes in the hip joints in patients with axial spondyloarthritis and axial psoriatic arthritis and to evaluate the relationship between coxitis and disease activity. Material and methods. The study included 222 patients with a mean age of 35.7±12.7 years. The first group included 108 patients who met the 2009 ASAS (Assessment of SpondyloArthritis International Society) criteria for axSpA or the 1984 criteria for ankylosing spondylitis (AS); The second group included 114 patients with axPsA who met the CASPAR (ClASsification for Psoriatic ARthritis) criteria. Signs of axial involvement in psoriatic arthritis (PsA) were determined using instrumental imaging methods. Diagnosis required the presence of radiologically reliable sacroiliitis (SI), i.e., bilateral stage ≥II or unilateral stage ≥III according to Kellgren, or active sacroiliitis according to magnetic resonance imaging. The presence of at least one syndesmophyte (paraspinal ossificate) in the cervical (CS) or lumbar (LS) spine, as well as ankylosis of the facet joints of the CS, were also taken into account. The mean age of disease onset was 26.3±20.3 years; HLA-B27 was detected in 54% of patients. The diagnosis of coxitis was established based on a pelvic X-ray and calculation of the Bath Ankylosing Spondylitis Radiology Hip Index (BASRI hip) for each joint. Results. Radiographic evidence of coxitis was detected in 52 of the 222 patients included in the study, including 22 patients with AS and 30 patients with axPsA. Patients with axPsA were older than those with axSpA (median age 32 years and 45 years, respectively; pConclusion. Radiographic coxitis was detected in 20% of patients with axSpA and 26% with axPsA. In previous studies, the incidence of radiographic coxitis in patients with psoriatic arthritis did not exceed 10%. According to our study, patients with axPsA had high clinical and laboratory indicators of disease activity, as well as significant functional impairment.
- 2 March 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (1) , 53-59
Open AccessFeatures of coxitis in spondyloarthritis
According to an epidemiological study, hip joint involvement was detected in 12–56% of patients with axial spondyloarthritis (axSpA) in Russia. Data on the incidence of coxitis in patients with axial psoriatic arthritis (axPsA) are lacking. The aim of the study was to compare radiographic changes in the hip joints in patients with axial spondyloarthritis and axial psoriatic arthritis and to evaluate the relationship between coxitis and disease activity. Material and methods. The study included 222 patients with a mean age of 35.7±12.7 years. The first group included 108 patients who met the 2009 ASAS (Assessment of SpondyloArthritis International Society) criteria for axSpA or the 1984 criteria for ankylosing spondylitis (AS); The second group included 114 patients with axPsA who met the CASPAR (ClASsification for Psoriatic ARthritis) criteria. Signs of axial involvement in psoriatic arthritis (PsA) were determined using instrumental imaging methods. Diagnosis required the presence of radiologically reliable sacroiliitis (SI), i.e., bilateral stage ≥II or unilateral stage ≥III according to Kellgren, or active sacroiliitis according to magnetic resonance imaging. The presence of at least one syndesmophyte (paraspinal ossificate) in the cervical (CS) or lumbar (LS) spine, as well as ankylosis of the facet joints of the CS, were also taken into account. The mean age of disease onset was 26.3±20.3 years; HLA-B27 was detected in 54% of patients. The diagnosis of coxitis was established based on a pelvic X-ray and calculation of the Bath Ankylosing Spondylitis Radiology Hip Index (BASRI hip) for each joint. Results. Radiographic evidence of coxitis was detected in 52 of the 222 patients included in the study, including 22 patients with AS and 30 patients with axPsA. Patients with axPsA were older than those with axSpA (median age 32 years and 45 years, respectively; pConclusion. Radiographic coxitis was detected in 20% of patients with axSpA and 26% with axPsA. In previous studies, the incidence of radiographic coxitis in patients with psoriatic arthritis did not exceed 10%. According to our study, patients with axPsA had high clinical and laboratory indicators of disease activity, as well as significant functional impairment.
- Open Access
- 24 June 2021
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (3) , 57-61
Significance of asymptomatic hyperuricemia in ankylosing spondylitis
Over the past decades, there has been an increase in the incidence of asymptomatic hyperuricemia (AHU), which includes an increased level (>360 μmol/L) of uric acid (UA) in the blood serum of patients with no clinical manifestations of gout. AHU is reported in various rheumatic diseases, mainly in osteoarthritis, in which AHU is one of the manifestations of the metabolic syndrome. There is relationship between AHU and pulmonary hypertension in systemic sclerosis, arterial hypertension (AH) in men with seronegative rheumatoid arthritis, extensive cutaneous psoriasis and metabolic disorders in psoriatic arthritis. There are almost no data on AHU in ankylosing spondylitis (AS), which served objective for this work.Objective: to assess the association of AHU with AS duration and activity and the presence of comorbid diseases.Patients and methods. A retrospective analysis of 48 medical histories of patients with diagnosed AS, who were treated in V.A. Nasonova Research Institute of Rheumatology from 2015 to 2019 years, whose serum UA level was >360 μmol/L.Results and discussion. More than half of patients with AS and AHU were overweight, 21% were obese. AH was diagnosed in 43.7% of patients. Stage II–III chronic kidney disease was detected in 16.7% of patients, urolithiasis – in 18.8%. 4 (8.3%) patients had diabetes mellitus. The serum UA level in patients with AS was 422.0 ± 61.6 μmol/L. In patients with AS, an association between AHU and age, duration and disease activity was noted. There was no statistically significant rela- tionship between HG and blood glucose, cholesterol, creatinine levels, body mass index. Correlation analysis revealed a statistically significant relationship between the glomerular filtration rate (GFR) and the age of patients (r=-0.54, pConclusion. In AS, an association between an increased level of UA in the blood serum and the duration and activity of the disease, and patient's age, was established.
- 24 June 2021
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (3) , 57-61
Open AccessSignificance of asymptomatic hyperuricemia in ankylosing spondylitis
Over the past decades, there has been an increase in the incidence of asymptomatic hyperuricemia (AHU), which includes an increased level (>360 μmol/L) of uric acid (UA) in the blood serum of patients with no clinical manifestations of gout. AHU is reported in various rheumatic diseases, mainly in osteoarthritis, in which AHU is one of the manifestations of the metabolic syndrome. There is relationship between AHU and pulmonary hypertension in systemic sclerosis, arterial hypertension (AH) in men with seronegative rheumatoid arthritis, extensive cutaneous psoriasis and metabolic disorders in psoriatic arthritis. There are almost no data on AHU in ankylosing spondylitis (AS), which served objective for this work.Objective: to assess the association of AHU with AS duration and activity and the presence of comorbid diseases.Patients and methods. A retrospective analysis of 48 medical histories of patients with diagnosed AS, who were treated in V.A. Nasonova Research Institute of Rheumatology from 2015 to 2019 years, whose serum UA level was >360 μmol/L.Results and discussion. More than half of patients with AS and AHU were overweight, 21% were obese. AH was diagnosed in 43.7% of patients. Stage II–III chronic kidney disease was detected in 16.7% of patients, urolithiasis – in 18.8%. 4 (8.3%) patients had diabetes mellitus. The serum UA level in patients with AS was 422.0 ± 61.6 μmol/L. In patients with AS, an association between AHU and age, duration and disease activity was noted. There was no statistically significant rela- tionship between HG and blood glucose, cholesterol, creatinine levels, body mass index. Correlation analysis revealed a statistically significant relationship between the glomerular filtration rate (GFR) and the age of patients (r=-0.54, pConclusion. In AS, an association between an increased level of UA in the blood serum and the duration and activity of the disease, and patient's age, was established.
- Open Access
- 27 April 2020
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 58 (2) , 232-237
THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
Тяжелое течение анкилозирующего спондилита с резистентностью к медикаментозной терапии
- 27 April 2020
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 58 (2) , 232-237
Open AccessTHE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
Тяжелое течение анкилозирующего спондилита с резистентностью к медикаментозной терапии